無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

中国の麻疹・おたふく風邪・風疹 (MMR) ワクチン産業

Research Report on China's Measles, Mumps and Rubella (MMR) Vaccine Industry, 2018-2022

発行 China Research and Intelligence 商品コード 584391
出版日 ページ情報 英文 40 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.73円で換算しております。
Back to Top
中国の麻疹・おたふく風邪・風疹 (MMR) ワクチン産業 Research Report on China's Measles, Mumps and Rubella (MMR) Vaccine Industry, 2018-2022
出版日: 2017年11月21日 ページ情報: 英文 40 Pages
概要

当レポートでは、中国の麻疹・おたふく風邪・風疹 (MMR) ワクチン産業について調査分析し、政府政策、供給状況、ロットリリース状況、需要状況、主要メーカー、競合、市場機会、リスクと課題、市場の見通しについて、体系的な情報を提供しています。

第1章 中国のワクチン産業の発展環境

  • 経済環境
  • 中国のワクチン産業の政策環境
  • 中国の人口規模と構造
  • 中国の医療産業の概要
  • 中国のワクチン市場の概要

第2章 中国の麻疹・おたふく風邪・風疹 (MMR) ワクチン市場の概要

  • 麻疹・おたふく風邪・風疹の流行状況
  • 中国の全国予防接種プログラムのワクチン接種規則

第3章 中国の麻疹・おたふく風邪・風疹 (MMR) ワクチン市場の分析

  • ロットリリースの状況
  • 市場規模
  • 競合分析

第4章 中国の麻疹・おたふく風邪・風疹 (MMR) ワクチン主要メーカー

  • 麻疹・おたふく風邪・風疹 (MMR) 混合ワクチン
    • Shanghai Institute of Biological Products Co., Ltd.
    • Beijing Tiantan Biological Products Co., Ltd.
  • 弱毒生麻疹ワクチン
    • Beijing Bio-Institute Biological Products Co., Ltd.
    • Changchun Keygen Biological Products Co., Ltd.
    • Wuhan Institute of Biological Products Co., Ltd.
  • 弱毒生麻疹・風疹混合ワクチン
    • Beijing Minhai Biological Products Co., Ltd.
    • Beijing Bio-Institute Biological Products Co., Ltd.
  • 弱毒生麻疹・おたふく風邪混合ワクチン
    • Shanghai Institute of Biological Products Co., Ltd.
    • Wuhan Institute of Biological Products Co., Ltd

第5章 中国の麻疹・おたふく風邪・風疹 (MMR) ワクチン市場の見通し

  • 発展の影響要因
  • 供給予測
  • 需要予測
目次
Product Code: 1711572

Description

Measles, mumps and rubella are acute respiratory infectious diseases caused by viruses, all of which can be spread through droplets coming from respiratory tracts. Children and teenagers are high risk groups of diseases. Breakout of epidemics among groups will not only result in harms to their health but also have a direct impact on normal teaching orders and even cause social panics.

Measles has the highest incidence rate and mortality rate, posing extremely huge threats to children's health. People infected with measles usually have clinic manifestations like fever, rashes and cold. Although rubella and mumps exhibit slight clinic symptoms and favorable prognosis, mumps sometimes brings about serious complications, such as boys with secondary orchitis and girls with secondary ovaritis, further leading to sterility and infertility when they grow up. If women are infected with measles at the early stage of pregnancy, there is a possibility of abortion and fetal malformation.

CRI analyzes that despite reduced incidence rates of measles, rubella and mumps in China in recent years, there is still a big gap between the actual incidence rate of measles and the targeted incidence rate set by WHO, which is required to be less than 1/ 1 million people.

In 2012, China's incidence rate of measles was recorded the lowest, which was only 4.6/ 1 million people, but this rate has shown an uptrend since 2013. The incidence rates of rubella and mumps demonstrated an overall declining trend between 2012 and 2016.

According to CRI, there have been four mainstream vaccines related to measles, rubella and mumps in China by the end of 2017. (1) Measles live attenuated vaccines: five enterprises hold production permits. (2) Measles-mumps combined live attenuated vaccines: two enterprises hold production permits. (3) Measles-rubella combined live attenuated vaccines: two enterprises hold production permits. (4) Measles-mumps-rubella combined live attenuated vaccine (measles-mumps-rubella vaccine): two enterprises hold production permits. In addition, imported measles-mumps-rubella vaccines produced by Glaxo SmithKline are launched into the Chinese market, namely Priorix. Although several enterprises possess production permits of MMR vaccines in China, a part of them have ceased production.

Research by CRI suggests that the sales volume of MMR vaccines exhibited a fluctuating trend in China between 2013 and 2017. This fluctuation is mainly attributed to factors such as government policies and market demand. In 2016, the sales volume of MMR vaccines exceeded 70 million.

The MMR vaccine is gradually taking up the market shares of other vaccines because of its good effect, preventing three types of infectious diseases.

Since 2008, the domestic MMR vaccine has been included in China's planned immunization, and provided free for children of appropriate ages by the government. This measure has promoted the development of the MMR vaccine industry in China. From a long-term perspective, MMR vaccines are expected to be the mainstream products, which will gradually substitute monovalent and combined vaccines.

CRI predicts a promising prospect of the MMR vaccine market since the loosing birth control policy is projected to contribute to an annual newborn population of 20 million or more in China during 2018 and 2022. It is estimated that the market shares of MMR vaccines will rise from 70% in 2017 to over 90% in 2022.

Readers can obtain the following information or more through this report:

  • Government Policies of China MMR Vaccines
  • Supply Status of MMR Vaccines in China
  • Lot Release Status of MMR Vaccines
  • Demand Status of MMR Vaccines in China
  • MMR Vaccine Manufacturers in China
  • Competition in China MMR Vaccine Industry
  • Market Opportunities and Driving Forces of China MMR Vaccine Industry
  • Risks and Challenges Faced by China MMR Vaccine Industry
  • Prospect of China MMR Vaccine Market, 2018-2022

Table of Contents

1 Development Environment of China Vaccine Industry, 2015-2018

  • 1.1 Economic Environment
  • 1.2 Policy Environment of China Vaccine Industry
    • 1.2.1 Primary Policies
    • 1.2.2 Lot Release System
  • 1.3 Population Size and Structure in China
  • 1.4 Overview of China Medical Industry
  • 1.5 Overview of China Vaccine Market

2 Overview of China MMR Vaccine Market, 2013-2017

  • 2.1 Epidemic Situations of Measles, Mumps and Rubella in China
    • 2.1.1 Measles
    • 2.1.2 Mumps
    • 2.1.3 Rubella
    • 2.1.4 MMR Vaccine
  • 2.2 Rules of Vaccination Procedures of China National Immunization Program

3 Analysis on China MMR Vaccine Market, 2013-2017

  • 3.1 Status of Lot Release
    • 3.1.1 Measles Live Attenuated Vaccine
    • 3.1.2 Measles-Mumps Combined Live Attenuated Vaccine
    • 3.1.3 Measles-Rubella Combined Live Attenuated Vaccine
    • 3.1.4 Measles-Mumps-Rubella (Combined) Vaccine
  • 3.2 Market Scale
    • 3.2.1 Market Size of Measles Live Attenuated Vaccines
    • 3.2.2 Market Size of Measles-Rubella Combined Live Attenuated Vaccines
    • 3.2.3 Market Size of MMR Combined Live Attenuated Vaccines
  • 3.3 Analysis on Competition in China MMR Vaccine Market, 2016-2018
    • 3.3.1 Barriers to Entry
    • 3.3.2 Competition Structure

4 Major MMR Vaccine Manufacturers in China, 2015-2018

  • 4.1 MMR Combined Vaccine
    • 4.1.1 Shanghai Institute of Biological Products Co., Ltd.
    • 4.1.2 Beijing Tiantan Biological Products Co., Ltd.
  • 4.2 Measles Live Attenuated Vaccine
    • 4.2.1 Beijing Bio-Institute Biological Products Co., Ltd.
    • 4.2.2 Changchun Keygen Biological Products Co., Ltd.
    • 4.2.3 Wuhan Institute of Biological Products Co., Ltd.
  • 4.3 Measles-Rubella Combined Live Attenuated Vaccine
    • 4.3.1 Beijing Minhai Biological Products Co., Ltd.
    • 4.3.2 Beijing Bio-Institute Biological Products Co., Ltd.
  • 4.4 Measles-Mumps Combined Live Attenuated Vaccine
    • 4.4.1 Shanghai Institute of Biological Products Co., Ltd.
    • 4.4.2 Wuhan Institute of Biological Products Co., Ltd.

5 Prospect of China MMR Vaccine Market, 2018-2022

  • 5.1 Factors Influencing Development
    • 5.1.1 Market Opportunities and Driving Forces
    • 5.1.2 Risks and Challenges
  • 5.2 Forecast on Supply of MMR Vaccines in China, 2018-2022
  • 5.3 Forecast on Demand for MMR Vaccines in China, 2018-2022

Selected Charts

  • Chart Population Size in China, 2001-2016
  • Chart Population Structure in China, 2003-2015
  • Chart Newborn Population in China, 2001-2016
  • Chart Medical and Health Expenditure in China, 2001-2016
  • Chart Medical and Healthcare Expenditure Per Capita in China, 2001-2016
  • Chart Incidence Situation of Measles in China, 2001-2016
  • Chart Incidence Situation of Rubella in China, 2001-2016
  • Chart Lot Release Volume of MMR-Type Vaccines in China, 2013-2017
  • Chart Lot Release Volume of Measles Live Attenuated Vaccines in China, 2012-2017
  • Chart Lot Release Volume of Measles-Mumps Combined Live Attenuated Vaccines in China, 2012-2017
  • Chart Lot Release Volume of Measles-Rubella Combined Live Attenuated Vaccines in China, 2012-2017
  • Chart Lot Release Volume of MMR Vaccines in China, 2012-2017
  • Chart Market Size of Measles Live Attenuated Vaccines in China, 2013-2017
  • Chart Market Size of Measles-Rubella Combined Live Attenuated Vaccines in China, 2013-2017
  • Chart Market Size of MMR Vaccines in China, 2013-2017
  • Chart Lot Release Volume of MMR Vaccines of Shanghai Institute of Biological Products Co., Ltd., 2010-2017
  • Chart Production Volume of MMR Vaccines of Beijing Tiantan Biological Products Co., Ltd.
  • Chart Forecast on Lot Release Volume of MMR Vaccines in China, 2018-2022
  • Chart Forecast on Market Size of MMR Vaccines in China, 2018-2022
Back to Top